Since 2007 the Claudia von Schilling Prize has been recognizing outstanding achievements in breast cancer research. Kirsten Kübler's honored study shows that tamoxifen directly activates a key cellular signaling pathway a central driver in the development of sporadic uterine cancers, thereby challenging previously accepted models of therapy-related cancer development. The laudatory speech states, among other things: “The study thus not only delivers scientifically outstanding results, but also provides concrete impetus for improving treatment safety and combines fundamental findings with a clear perspective for patients.”
Publication
Kübler, K., Nardone, A., Anand, S. et al. Tamoxifen induces PI3K activation in uterine cancer. Nat Genet57, 2192–2202 (2025). https://doi.org/10.1038/s41588-025-02308-w
